Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes

The combination of high affinity IL-2 receptor agonists and immunosuppressants specifically expands antigen-specific regulatory T cells, addressing the limitations of conventional immunosuppressants by enhancing T-cell regulation and reducing autoimmune disease-related immune responses.

WO2024229350A1PCT designated stage expired Publication Date: 2024-11-07CARTESIAN THERAPEUTICS INC +2
View PDF 41 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027671
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-03
Filing Date
2024-05-03
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Conventional immunosuppressants are broad-acting and often result in severe side effects, requiring lifelong therapy, while they fail to specifically target undesired immune responses associated with autoimmune diseases like diabetes, necessitating a more targeted approach to enhance regulatory T-cell production and durability.

Method used

Combining high affinity IL-2 receptor agonists with immunosuppressants, such as rapamycin, to synergistically induce and expand antigen-specific regulatory T cells, reducing CD8+ T cells and increasing double-negative T cells, thereby promoting tolerogenic immune responses.

Benefits of technology

This combination therapy effectively enhances the production and durability of antigen-specific regulatory T cells, reducing undesired immune responses and potentially treating or preventing autoimmune diseases like Type 1 diabetes with fewer side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024027671_07112024_PF_FP_ABST
    Figure US2024027671_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for enhancing regulatory T cells, including antigen- specific regulatory T cells, such as to treat or prevent diabetes (e.g., Type 1 diabetes).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Apoptosis-mimicking synthetic entities and use thereof in medical treatment

    US20020086049A1

  • Targeted and high density drug loaded polymeric materials

    US20060002852A1

  • Molecular antigen array

    US20060222652A1

  • Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use

    US20060251677A1

  • nanoparticles

    US20080145441A1